Jul. 2 at 11:53 AM
$IGC IGC is entering its biggest catalyst yet. 🚀
Phase 2 CALMA enrollment is complete, all 146 patients are locked in, and now the market is waiting for the data. The enrollment risk is gone—it’s all about the readout.
IGC-AD1 targets Alzheimer’s-related agitation, a multi-billion-dollar unmet market with very few effective treatment options. If the Phase 2 results are positive, IGC could quickly move onto the radar for licensing, partnerships, or acquisition discussions.
What makes this even more interesting? IGC has funded its own clinical development, giving it flexibility if the data is strong. Positive results could attract interest from biotech and pharma leaders looking to expand their neuroscience pipelines.
$LLY $BIIB $MRK $PFE 👀
#Biotech #Alzheimers #Phase2 #ClinicalTrials #BigPharma #IGCPharma #Bullish
